Pediatric TB Intensive Houston, Texas

Similar documents
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Pediatric TB Intensive San Antonio, Texas October 14, 2013

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

At the end of this session, participants will be able to:

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012

Tuberculosis Intensive

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

TB Intensive San Antonio, Texas

Treatment of Active Tuberculosis

Diagnosis and Medical Management of Latent TB Infection

TB Intensive San Antonio, Texas August 7-10, 2012

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

LTBI Videos-Treatment

Contact Investigation and Prevention in the USA

LTBI in Special Populations John Nava, MD October 5, 2010

Management of Immune Reconstitution Inflammatory Syndrome (IRIS)

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Drug Interactions Lisa Armitige, MD, PhD November 17, 2010

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

Errors in Dx and Rx of TB

Tuberculosis: A Provider s Guide to

Chapter 5 Treatment for Latent Tuberculosis Infection

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Diagnosis and Treatment of Tuberculosis, 2011

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Treatment of Tuberculosis

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Managing Complex TB Cases Diana M. Nilsen, MD, RN

has the following disclosures to make:

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

Case Management of the TB/HIV Infected Patient

Standard TB Treatment

Pediatric Tuberculosis: The Essentials October 8, 2014

Fundamentals of Tuberculosis (TB)

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

Communicable Disease Control Manual Chapter 4: Tuberculosis

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

PEDIATRIC TUBERCULOSIS. Objectives. Children are not just small adults. Pediatric Tuberculosis 1

Treatment of Tuberculosis Disease. Treatment of Tuberculosis. Decision to Treat Initiation of Therapy 1

PEDIATRIC TUBERCULOSIS

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

TB Intensive Houston, Texas October 15-17, 2013

CNS Infections in the Pediatric Age Group

CHAPTER 3: DEFINITION OF TERMS

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

TB Nurse Case Management

Tuberculosis: update 2013

TB in the Correctional Setting Florence, Arizona October 7, 2014

Treatment of Tuberculosis

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Tuberculosis Tools: A Clinical Update

Disclosures. Current Issues and Controversies in Child and Adolescent Tuberculosis 02/24/2016. NSTC 2016 Annual Meeting

TB Intensive San Antonio, Texas May 7-10, 2013

Gary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!!

Pediatric Tuberculosis

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

Pediatric Tuberculosis

Supplementary Appendix

TB in Corrections Phoenix, Arizona

Pediatric Tuberculosis

TB in the Patient with HIV

Treatment of Tuberculosis

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None

Jeffrey R. Starke, M.D. has the following disclosures to make:

Immune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela

CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease

Research in Tuberculosis: Translation into Practice

Pediatric Tuberculosis

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Tuberculosis (TB) Fundamentals for School Nurses

Northwestern Polytechnic University

Disclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t

10. TB and HIV Infection

TUBERCULOSIS. Pathogenesis and Transmission

Treatment and Monitoring

Pediatric TB Theresa Barton, MD

Monica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale

Treatment of Latent TB Infection (LTBI)

Dosage and Administration

Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD

Pediatric TB Intensive Houston, Texas October 14, 2013

Management of Drug-resistant Tuberculosis (DR-TB)

Treatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27

Pediatric TB Intensive Houston, Texas

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

3/25/2012. numerous micro-organismsorganisms

TB Intensive San Antonio, Texas November 11 14, 2014

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Pediatric TB Intensive Houston, Texas October 14, Extrapulmonary TB in Children Kim Connelly Smith, MD, MPH October 14, 2013

Tuberculosis Intensive

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines:

Transcription:

Pediatric TB Intensive Houston, Texas November 13, 2009 Treatment of Pediatric TB Jeffrey R. Starke, M.D. November 13, 2009 MANAGEMENT OF CHILDHOOD TUBERCULOSIS Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine 1

DRUG RESISTANCE IN TUBERCULOSIS The development of drug resistance in M. tuberculosis is the result of a conspiracy among the organism, the patient, t the doctor and the healthcare system! DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS genetic loci for resistance on chromosome, unlinked resistance of drugs independent frequency of mutations at loci is known more likely to have mutations when mycobacterial population is larger : infection vs. disease 2

3

TREATMENT OF TUBERCULOSIS More bugs, more drugs! Question: When does tuberculosis infection turn into tuberculosis disease? When do we cross the threshold or using more than one drug? 4

TB DRUGS IN CHILDREN Isoniazid: [10 15 mg/kg/day] Well tolerated with few AEs Both hepatitis and neuritis are rare Better tolerated with food in stomach Poor tolerance of suspension > 5 kg Rifampin: [10 15 mg/kg/day] Well tolerated; only rare AEs Watch for contact lenses Can t use OCPs for birth control TB DRUGS IN CHILDREN Pyrazinamide: [30 40 mg/kg/day] Large pill, no standard d suspension itching > joint pain > hepatitis Ethambutol: [20 mg/kg/day] Ocular toxicity very, very rare Watch for renal disease [elimination] Now standard 4 th drug for children 5

TB DRUGS IN CHILDREN Aminoglycosides: Mostly CNS, drug-resistant resistant TB Amikacin preferred for CNS [more resistance to streptomycin] Oto- and renal toxicity possible Ethionamide: [15 mg/kg/day] Excellent drug for CNS TB Difficult-to-use dosage form GI intolerance, but less than in adults TB DRUGS IN CHILDREN Fluoroquinolones: Used for drug-resistant resistant TB or intolerance to standard drugs Few studies, mostly ciprofloxacin Dosages unknown for moxafloxacin and gatifloxacin Levofloxacin: twice daily dosing for children < 5 years of age 6

DIRECTLY OBSERVED THERAPY FOR TUBERCULOSIS means a dispassionate 3rd party is actually present when medications are taken with every dose standard of care in U.S. for treating tuberculosis disease desirable for high risk infections - newborns and infants, household contacts, HIV - infected or immune compromised TUBERCULOSIS IN CHILDREN TREATING EXPOSED CHILDREN Very high rate of infection Takes up to 3 months for the skin test to turn positive U.S. studies 10% to 20% of childhood TB cases can be prevented if children exposed in a household receive isoniazid Assume young children are infected until proven they are not 7

TREATING TB EXPOSED CHILDREN Usually treat for 8 to 10 weeks after exposure has been broken by loss of contact or treatment Must follow both the patient and the source case [sputum conversion, drug susceptibility pattern, contact] Infants:? TST or IGRA reliable if child < 6 months of age [little data] 8

TREATMENT OF LTBI IN CHILDREN 9 months of isoniazid (daily or twice weekly under DOT) is only accepted regimen INH-resistance/intolerance rifampin for 4-6 months Multidrug-resistance lid resistance consult an expert Use isoniazid unless there is documented exposure to a specific case of drug-resistant resistant TB ALTERNATIVE REGIMENS FOR LTBI INH for 6 months Rifampin for 4-6 months INH + RIF for 3-4 months 9

PEARLS OF WISDOM FOR TREATING LTBI Use INH suspension only in children 5 kg Use DOPT for: recent contacts, infants, immune compromised When children aren t tolerating INH, the problem is more often with the parent than the child Routine LFTs only for: other liver toxic drugs, liver disease, signs or symptoms of hepatitis Pyridoxine needed only for breast- feeding infants, pregnancy, poor diets TREATMENT OF TUBERCULOSIS DISEASE IN CHILDREN Pulmonary INH, RIF for 6 months + PZA for first 2 months Add EMB initially if risk of INH resistance Can be q.day or twice weekly INH-resistant: RIF+PZA+EMB for 9 months MDR - depends on susceptibility - at least 18 months CNS, Disseminated usually start with 4 drugs (INH, RIF, PZA + EMB) usual length: 9-12 months q.day initially, may use twice weekly later 10

TREATMENT RULE OF THUMB FOR CNS TUBERCULOSIS Treatment for tuberculous meningitis should be started, while the work-up is being undertaken, for any child with meningitis, no obvious cause [such as a positive Gram stain] and any of: basilar enhancement, hydrocephalus, cranial nerve abnormality, infarction, possible tuberculoma TREATMENT OF TUBERCULOUS MENINGITIS Medications Always start at least 4 anti-tb drugs 1. Isoniazid 2. Rifampin 3. Pyrazinamide 4. Ethionamide or an aminoglycoside Always start corticosteroids [4-6 weeks] 11

TREATMENT OF TUBERCULOUS MENINGITIS Other Measures Fluid/electrolyte management Airway management Seizure control Ventriculostomy or VP shunt Physical therapy TREATMENT OF LYMPHATIC TUBERCULOSIS Biggest problem is differentiating TB from NTM adenitis and Bartonella Surgical Approach 1. Fine needle aspirate 2. Incision and drainage [Not!] 3. Excisional biopsy 12

TREATMENT OF LYMPHATIC TUBERCULOSIS Can use standard anti-tb regimens Relapse/recrudescence rates are fairly high Empiric regimen for mycobacterial lymphadenitis: INH+RIF+EMB+Clarithromycin [covers TB, M. bovis, many NTM] 13

TUBERCULOSIS IN CHILDREN IMPACT OF DRUG-RESISTANCE RESISTANCE Usually must link the child with an adult case to identify it Adults with drug-resistant resistant TB are as contagious as those with susceptible disease Disease expression ess in children the same as with susceptible strains Children tolerate and respond well to second- line drugs 14

PRINCIPLES OF TREATING MDR TUBERCULOSIS IN CHILDREN Exposure: often don t treat Infection: two best available drugs Disease: usually 4 to 6 drugs, best available PRINCIPLES OF TREATING DRUG- RESISTANT TB IN CHILDREN 1. Get susceptibility pattern 2. LTBI: RIF if susceptible; if resistant to both INH and RIF, use two best drugs PZA+EMB or PZA+quinolone; 9-12 mos. 3. Disease: Need 2 cidal drugs, if possible, plus at least 2 other drugs daily therapy only INH-R: 9 months of therapy MDR: at least 12 months of therapy XDR:??? 15

25 YEAR EXPERIENCE WITH DRUG RESISTANT TB IN CHILDREN Jeffrey Starke, MD Lydia Ong, PA-C and Andrea Cruz, MD 158 patients: 65 exposure, 55 infection, 38 disease 79 MDR-TB: 41 exposure, 28 infection, 10 disease Resistance: INH 150, RIF 103, PZA 33, EMB-27 No child with exposure or infection progressed to disease All children with disease had resolution For 76% of patients, drug resistance known at onset of treatment [contact investigation] Adverse reactions very infrequent CORTICOSTEROIDS IN PEDIATRIC TUBERCULOSIS Useful when host inflammatory response is contributing to tissue damage or dysfunction meningitis endobronchial miliary with alveolar block pericardial with constriction vertebral with spinal root irritation Can use prednisone or dexamethasone 16

TREATMENT OF TB IN HIV- INFECTED CHILDREN Respond well to standard regimens Use 4 drugs initially for TB disease Length of therapy 9-12 months Rifampin drug interactions a problem *can give rifampin for 1-2 months, then change to other TB drugs *can use rifabutin [though few data for children, esp. infants] TREATING TB IN IATROGENICALLY IMMUNE SUPPRESSED CHILDREN Corticosteroids, anti-tnf antibodies, cancer chemotherapy, anti-rejection drugs Need to stop the immunosuppression as much as possible for at least 4-6 weeks, longer for anti-tnf antibodies Case-by-case basis 17

MOST COMMON REPORTED ADVERSE REACTIONS TO ANTI-TB TB DRUGS IN CHILDREN Upset stomach [all] Loose stools [INH suspension] Decreased appetite [? all] Change in behavior [? not related] Headaches [esp. INH;? Not related] Itching [PZA] Sore joints and muscles [PZA] Signs of peripheral neuritis [INH] DEALING WITH LIVER TOXICITY IN CHILDREN More common with severe TB disease, especially early on More common with underlying liver abnormality or co-administration of hepatotoxic drugs [anticonvulsants] Most common in first two months, but can occur at any time *Warn parents: Stop drugs first, call me second [child on INH alone] 18

DEALING WITH LIVER TOXICITY IN CHILDREN Check liver enzymes for vomiting, abdominal pain and/or jaundice Liver sparing regimen: ethambutol, aminoglycoside, fluoroquinolone Restart drugs one at a time; check liver enzymes after 3-5 days for each PZA is most expendable drug FOLLOW-UP EVALUATIONS FOR CHILDREN WITH TUBERCULOSIS skin test stays positive forever frequent chest x-rays unnecessary: at diagnosis, 1-2 months, end of therapy follow growth & development closely adequate nutrition routine liver enzyme monitoring not necessary routine vitamin B 6 not necessary except breast-feeding, pregnant adolescents, poor diet 19

IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME [IRIS] happens in a variety of situations when severely immunocompromised patients have rapid restoration of immune function e.g.: neutropenic cancer patients with Candidemia in HIV, a/w a variety of organisms, including mycobacteria, CMV, hepatitis B and C viruses, HSV, JC virus (progressive multifocal leucoencephalopathy), Pneumocystis, Cryptococcus, leishmaniasis, cerebral toxoplasmosis Mycobacteria account for 40% of the cases IRIS AND MYCOBACTERIA So-called paradoxical reactions occur in 2% to 23% of HIV-negative adult patients receiving treatment for tuberculosis Most common features are fever and lymph node enlargement, though respiratory failure and neurologic deterioration also occur Median time is 40-90 days after TB treatment is started Abnormality is at the original site of infection in 75% of cases, at a new location in 25% Mechanism: increased tumor necrosis factor 20

IRIS AND MYCOBACTERIA In HIV-uninfected children treated for tuberculosis, paradoxical reactions are common Enlarged hilar/mediastinal lymph nodes, tuberculomas are most common Changes may be only radiographic or clinical - stridor, respiratory distress, seizures (tuberculoma) Natural history vs. immune reconstitution IRIS AND MYCOBACTERIA Definition: presentation or clinical deterioration of an opportunistic infection in HIV-infected patients as a direct result of the enhancement of immune responses to those pathogens during HAART Strongest clue is usually a temporal association (30-90 days) No specific laboratory test available Clinical judgment is important (but may be nonspecific) Can also be a worsening of the opportunistic infection due to poor compliance, poor absorption or drug resistance Can also be a new infection or condition 21

IRIS IN CHILDREN Puthanakit et al. Pediatr Infect Dis J 2006; 25:53 32/153 (21%) HIV-infected Thai children developed d IRIS after starting HAART 14/32 (44%) episodes associated with mycobacteria [3-TB, 2-BCG, 7-MAC Complex, 2-other] In 11 of 14 patients, the mycobacterial infections had not been diagnosed prior to starting HAART 7 varicella-zoster, 7HSV, 3 Cryptococcus, 1 Guillain- Barre Children who developed IRIS had significantly lower baseline CD4 lymphocyte counts PREVENTION AND TREATMENT OF IRIS Watch out! CD4 lymphocyte count < 100 cells viral load > 10 5 copies/ml? if HAART should be delayed in patients with TB Must balance risk of IRIS with risk of other opportunistic infection if CD4 count stays low and viral load stays high Adjunctive treatment - only anecdotal evidence at present Oral corticosteroids can help when severe manifestations occur ( same as TB in HIV- uninfected children!) 22